Table 1.
Patient characteristics.
| Characteristics | All patients (n = 50) |
Small total BTS (n = 43) |
Large total BTS (n = 7) |
P-value |
|---|---|---|---|---|
| Age (years) | 72 (66–76) | 72 (65–76) | 74 (72–77) | 0.39 |
| <65 years | 7 (14.0) | 6 (14.0) | 1 (14.3) | |
| ≥65 years | 43 (86.0) | 37 (86.0) | 6 (85.7) | |
| Sex | 0.68 | |||
| Male | 33 (66.0) | 29 (67.4) | 4 (57.1) | |
| Female | 17 (34.0) | 14 (32.6) | 3 (42.9) | |
| Smoking status | 1.00 | |||
| Never | 3 (6.0) | 3 (7.0) | 0 | |
| Current or former | 47 (94.0) | 40 (93.0) | 7 (100.0) | |
| ECOG PS | 0.046 | |||
| 0 | 12 (24.0) | 12 (27.9) | 0 | |
| 1 | 27 (54.0) | 24 (55.8) | 3 (42.9) | |
| 2 | 10 (20.0) | 6 (14.0) | 4 (57.1) | |
| 3 | 1 (2.0) | 1 (2.3) | 0 | |
| 4 | 0 | 0 | 0 | |
| Stage | 1.00 | |||
| Post-treatment recurrence of LS | 2 (4.0) | 2 (4.7) | 0 | |
| ES | 48 (96.0) | 41 (95.4) | 7 (100.0) | |
| Programmed death-ligand 1 inhibitors | 1.00 | |||
| Atezolizumab | 43 (86.0) | 37 (86.0) | 6 (85.7) | |
| Durvalumab | 7 (14.0) | 6 (14.0) | 1 (14.3) | |
| Brain metastasis | 1.00 | |||
| No | 33 (66.0) | 28 (65.1) | 5 (71.4) | |
| Yes | 17 (34.0) | 15 (34.9) | 2 (28.6) | |
| Liver metastasis | 0.03 | |||
| No | 34 (68.0) | 32 (74.4) | 2 (28.6) | |
| Yes | 16 (32.0) | 11 (25.6) | 5 (71.4) | |
| Bone metastasis | 0.23 | |||
| No | 27 (54.0) | 25 (58.1) | 2 (28.6) | |
| Yes | 23 (46.0) | 18 (41.9) | 5 (71.4) | |
| Superior vena cava syndrome | 0.37 | |||
| No | 47 (94.0) | 41 (95.3) | 6 (85.7) | |
| Yes | 3 (6.0) | 2 (4.7) | 1 (14.3) | |
| NLR | 3.8 (2.6–5.2) | 3.4 (2.5–5.0) | 5.2 (2.9–13.7) | 0.07 |
| Low NLR (≤6.3) | 43 (86.0) | 39 (90.7) | 4 (57.1) | |
| High NLR (>6.3) | 7 (14.0) | 4 (9.3) | 3 (42.9) | |
| PLR | 211.3 (171.2–324.7) | 209.8 (153.2–319.6) | 218.3 (176.5–507.7) | 0.45 |
| Low PLR (≤173.9) | 15 (30.0) | 14 (32.6) | 1 (14.3) | |
| High PLR (>173.9) | 35 (70.0) | 29 (67.4) | 6 (85.7) | |
| Total BTS | 125.4 (99.3–166.1) | 117.0 (90.0–156.0) | 234.9 (195.7–254.0) | < 0.0001 |
| Small total BTS (≤183.2 mm) | 43 (86.0) | 43 (100.0) | 0 | |
| Large total BTS (>183.2 mm) | 7 (14.0) | 0 | 7 (100.0) |
Data are presented as n (%) or medians (interquartile ranges). Fisher’s exact test was used to compare the proportions of categorical data between the groups. The Mann–Whitney U-test was used to compare the numerical data between the groups. BTS, baseline tumor size; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ES, extensive-stage; IQR, interquartile range; LS, limited-stage; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio